Literature DB >> 16531422

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye.

B R Kosobucki1, W R Freeman, L Cheng.   

Abstract

AIM: To determine the duration of residence of triamcinolone in the vitrectomised eye.
METHODS: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery.
RESULTS: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise >/=10 mm Hg.
CONCLUSIONS: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531422      PMCID: PMC1860213          DOI: 10.1136/bjo.2005.088278

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  54 in total

Review 1.  Management of chronic uveitis.

Authors:  P J McCluskey; H M Towler; S Lightman
Journal:  BMJ       Date:  2000-02-26

2.  Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.

Authors:  R P Danis; T A Ciulla; L M Pratt; W Anliker
Journal:  Retina       Date:  2000       Impact factor: 4.256

3.  Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy.

Authors:  A Martidis; J S Duker; C A Puliafito
Journal:  Arch Ophthalmol       Date:  2001-09

4.  Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis.

Authors:  S Young; G Larkin; M Branley; S Lightman
Journal:  Clin Exp Ophthalmol       Date:  2001-02       Impact factor: 4.207

5.  Intravitreal triamcinolone and elevated intraocular pressure.

Authors:  R J Wingate; P E Beaumont
Journal:  Aust N Z J Ophthalmol       Date:  1999-12

6.  Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  J Glaucoma       Date:  2001-08       Impact factor: 2.503

7.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

8.  Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.

Authors:  R J Antcliff; D J Spalton; M R Stanford; E M Graham; T J ffytche; J Marshall
Journal:  Ophthalmology       Date:  2001-04       Impact factor: 12.079

9.  Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.

Authors:  J B Jonas; A Söfker
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

10.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.

Authors:  J B Jonas; J K Hayler; S Panda-Jonas
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

View more
  6 in total

1.  Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities.

Authors:  Ankur M Shah; Stephen F Oster; William R Freeman
Journal:  Am J Ophthalmol       Date:  2010-03       Impact factor: 5.258

2.  RECALCITRANT CYSTOID MACULAR EDEMA AFTER PARS PLANA VITRECTOMY.

Authors:  Mostafa R Alam; Cheryl A Arcinue; Nadia B Mendoza; William R Freeman
Journal:  Retina       Date:  2016-07       Impact factor: 4.256

3.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

4.  The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections.

Authors:  Ümit Yolcu; Güngör Sobaci
Journal:  Int Ophthalmol       Date:  2014-11-26       Impact factor: 2.031

5.  Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide).

Authors:  Suk Ho Byeon; Oh W Kwon; Ji Hun Song; Sung Eun Kim; Yong Sik Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

6.  Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy.

Authors:  Lingmin He; Annie Chan; Theodore Leng; Mark S Blumenkranz
Journal:  Clin Ophthalmol       Date:  2011-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.